Search
Houston Oncology Summit: Oppenheimer analyst Matthew Biegler talks about synthetic lethality
- blonca9
- Sep 21, 2023
- 1 min read
He describes how PARP inhibitors were initial successes and where the field is going now beyond PARP with new targets.
Brought to you by:
